Skip to main content

Boston Strategics, Molecular Response Ink Deal to Improve Oncology Rx Trial Success

NEW YORK (GenomeWeb) – Therapeutic research firm Boston Strategics and molecular diagnostic services shop Molecular Response have agreed to design and manage drug development programs together with the aim of identifying subpopulations of best responders to treatments and improving their probability of success through clinical trials.

The companies will identify best responder sub-populations using patient-derived tumor xenograft models, genomic profiling technologies, and Molecular Response's proprietary bank of tumor cells. The bank contains 144,000 cryopreserved specimens from common and rare tumor types collected from the US population over two decades.

In turn, Boston Strategics will contribute its oncology drug development expertise. Through this deal, Molecular Response will become a member of Boston Strategics' 'True' Open Innovation platform, which fosters collaborations with providers of innovative resources in oncology drug development research.

Recently, Molecular Response announced it had opened a CLIA-certified, purpose-built facility in San Diego for providing clinical trial support services to pharmaceutical partners.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.